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Abstract Vitronectin (Vn) exists in vivo in at least two different 
conformational states, the native and the modified form, and these 
forms have different ligand binding properties. To characterize 
the molecular events associated with this conformational f exibil- 
ity, modified Vn was analyzed by competitive ELISA using a 
panel of conformationally sensitive antibodies with known epi- 
topes. These studies provided evidence for major molecular ear- 
rangements upon the transition from the native to the modified 
form that are not limited to the C-terminal heparin binding do- 
main, but also occur in the N-terminal part of the molecule. 
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interaction with collagen [8], fl-endorphin [9], type 1 plasmino- 
gen activator inhibitor [10-12], urokinase receptor [13], incor- 
poration into the extracellular matrix [14,15], cell binding [16]), 
depend on exposure of the cryptic heparin-binding region, and 
the modified form of Vn has been postulated to act as a scaven- 
ger for 'spent' molecules (e.g. thrombin-antithrombin III com- 
plexes [17]). Taken together, these results indicate that Vn in 
vivo exist in at least two distinct states, and these forms have 
different ligand binding properties. In the present study, we 
provide evidence that conformational changes upon the transi- 
tion of the native to the modified form of the Vn molecule are 
not limited to the heparin binding domain. 
1. Introduction 
Vitronectin (Vn), an adhesive glycoprotein present in the 
circulation and in a variety of tissues, is a conformationally 
labile molecule (reviewed in [1,2]). While only 2% of Vn in 
plasma binds to heparin-Sepharose, the relative amount in- 
creases to approximately 7% by the generation of serum [3]. 
Similarly, the formation of disulfide bonded complexes of Vn 
with thrombin-antithrombin III, as well as its interaction with 
either heparin or with complement CSb-7, induces a conforma- 
tional change in the molecule, leading to the expression of the 
cryptic heparin binding domain and exposure of an epitope for 
a conformationally sensitive antibody (i.e. 8E6) [2], tentatively 
mapped to C-terminal Vn-fragments [4]. 
The structural basis for the conformational instability of Vn 
is only incompletely understood. It was suggested that hetero- 
polar interactions between the N-terminal ocated acidic do- 
main, and the pnlycationic heparin binding domain internally 
stabilize the entire molecule, which forces the heparin binding 
domain into a cryptic location within the native molecule as 
compared to an exposed position in the modified or denatured 
form [1]. Conformational changes in the Vn molecule are 
closely linked to a spontaneous formation of disulfide-linked 
multimers [5-7]. Interestingly, Vn present in the supernatant of
stimulated platelets is conformationally altered and multimeric 
[6]. 
The conversion of native to the conformationally altered, 
multimeric form appears to be critical for some of the functions 
of Vn. For example, a number of its binding properties (e.g., 
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2. Materials and methods 
2.1. Proteins and antibodies 
Native Vn was purified from pooled human plasma s described [18]. 
Modified Vn was obtained by incubation of native Vn (0.5/tM final 
concentration) in PBS at 55°C for 1 h as described [6]. For some 
experiments, olid urea was added to native Vn to a final concentration 
of 8 M, followed by incubation at37°C for 2 h and extensive dialysation 
against PBS. This form of Vn was designated 'urea-treated' native Vn. 
Human Vn was also purified by heparin affinity chromatography in the 
presence of 8 M urea [19]. The latter form is referred to as 'denatured' 
Vn. CNBr cleavage and acid hydrolysis of denatured Vn were per- 
formed as described [20]. Monoclonal antibodies (MAbs) 153 (directed 
against amino acids (aa) 1~,0) and 1244 (directed against aa 52-239) 
were obtained by standard hybridoma techniques using denatured Vn 
as immunogen 121]. The hybridoma clone producing MAb 8E6 (di- 
rected against aa 52-239; see Fig. 3) was kindly provided by Dr. D. 
Mosher (University of Wisconsin). MAbs were produced as ascites, and 
the resulting IgG was purified by using protein A-agarose (MAbs 153, 
1244) or by the caprylic acid method (MAb 8E6) [22]. Selected MAbs 
were biotinylated with NHS-LC-Biotin according to the manufacturer 
(Pierce). Antibodies against purified native human Vn were also raised 
in rabbits and the IgG fraction was purified by using protein A-agarose 
as described [23]. Protein concentration was estimated either by the 
bicinchoninic acid method using bovine serum albumin (BSA) as a 
standard (Pierce) or by spectrophotometric methods using reported 
absorption coefficients [1,22]. 
2.2. ELISA 
Conformational changes in the Vn molecule were quantified by com- 
petitive ELISA as described [7,24]. Briefly, microtiter wells were coated 
with denatured Vn (1 flg/ml in PBS; 4°C, 16 h), and non-specific bind- 
ing sites on the plastic dishes were blocked by incubating the washed 
wells for 1 h at 37°C in PBS containing 3% casein and 0.05% Tween 
80. The wells were co-incubated for 1 h with a constant amount of IgG 
and the indicated concentration f Vn in PBS containing 0.1% casein 
and 0.1% Tween 80. The following final concentrations of antibodies 
were used: 153 and 1244, 50 ng/ml; and MAb 8E6, 300 ng/ml. These 
concentrations were required for half-maximal binding in the absence 
of soluble Vn competitor (not shown). Bound IgG was detected with 
biotin-conjugated goat anti-mouse or anti-rabbit IgG, followed by 
streptavidin alkaline phosphatase conjugate and the chromogenic sub- 
strate p-nitrophenyl phosphate (Zymed). The change of absorbance at
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405 nm of duplicate wells was determined and the absorbance ofwells 
not incubated with antibodies but otherwise treated identically was 
subtracted. For cross-competition experiments, microtiter wells were 
coated with denatured Vn and blocked as above and incubated with a 
constant concentration f biotinylated MAb (at a concentration re- 
quired for half-maximum binding) in the presence ofincreasing concen- 
trations of unlabeled antibodies for 1 h at 37°C. After washing, bound 
biotinylated MAbs were detected with streptavidin alkaline phosphat- 
ase conjugate, followed by the chromogenic substrate. To determine the 
binding of Vn to heparin, microtiter wells were coated ( 1 mg/ml in PBS; 
4°C, 16 h) with porcine heparin (Sigma), blocked as above, and incu- 
bated with the indicated concentrations of Vn in PBS containing 0.1% 
casein and 0.1% Tween 80. Bound Vn was detected with rabbit anti- 
human Vn IgG (10/tg/ml; 1 h, 37°C), followed by biotin-conjugated 
goat anti-rabbit IgG, streptavidin alkaline phosphatase complex and 
chromogenic substrate. Results of duplicate wells were averaged and 
corrected for absorbance at405 nm from wells not incubated with Vn, 
but otherwise treated identically. 
2.3. Polyacrvlamide g l electrophoresis (PAGE) 
SDS-PAGE was performed in slab gels according to Laemmli [25]. 
The upper stacking el contained 4% acrylamide, while the lower re- 
solving gel contained 9% or 14% acrylamidc. Native PAGE was per- 
formed on 3% acrylamide (stacking gel) and 7.5% acrylamide (resolving 
gel) in the absence of SDS using the Laemmli buffer system as described 
[6]. Reduction of samples for native PAGE and SDS-PAGE was carried 
out by the addition of DTT (50 mM) to the sample buffer. In control 
experiments, he success of the reduction for the native PAGE system 
was tested using human two-chain urokinase. Non-reduced urokinase, 
with a reported isoelectric point of 9.4 [26] did not enter the gel, as 
expected from the pH of the discontinuous native PAGE, whereas the 
acidic A-chain of urokinase was separated upon reduction ( ot shown). 
After electrophoresis, the proteins in the gel were transferred onto 
nitrocellulose membranes and analyzed by immunoblotting using MAb 
1244 as described [21]. 
3. Results and discussion 
Interaction of Vn with physiological ligands, or denaturation 
of Vn by heat-treatment or protein denaturants, induces con- 
formational changes in the Vn molecule, followed by the forma- 
tion of disulfide-bonded multimers and exposure of the C- 
terminal heparin binding domain [2,6]. To characterize further 
the nature of the conformational changes in the Vn molecule 
associated with the transition from the native to the modified 
form, Vn was mildly denatured by heat-treatment as described 
[6]. The resulting modified Vn was characterized by SDS- 
PAGE and native PAGE to document the success of the de- 
naturation and compared to the electrophoretic mobility of 
native Vn (Fig. 1). Upon reduction, modified Vn co-migrated 
with the native form of the molecule on SDS-PAGE with the 
expected Mrs of 75,000 and 65,000 (Fig. 1, panel A). In contrast, 
when modified Vn was analyzed by SDS-PAGE under non- 
reducing conditions, the majority of the protein remained in the 
stacking el and failed to enter the separating gel (Fig. 1, panel 
B). This electrophoretic mobility is characteristic for multi- 
meric, modified Vn [6]. In contrast, native Vn migrated as a 
diffuse band between 75 and 65 kDa (Fig. 1, panel B, lane 1). 
The structure of the heat-induced Vn multimers was further 
analyzed by native PAGE. When modified Vn was fractionated 
by native PAGE under non-reducing conditions, the multimers 
remained in the stacking el, whereas the majority of the native 
Vn entered the separating gel (Fig. 1, panel C) and co-migrated 
with Vn present in plasma (not shown). In a related assay 
system, modified Vn was fractionated on native PAGE gels 
under educing conditions (Fig. 1, panel D). Also under these 
conditions, the majority of the modfied Vn failed to enter the 
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Fig. 1. Heat-treatment i duces covalently- and non-covalently stabi- 
lized Vn multimers. Purified native Vn (lanes 1) was heated at 55°C for 
1 h (lanes 2), fractionated by SDS-PAGE under educing (panel A) and 
non-reducing (panel B) conditions, and by native PAGE under non- 
reducing (panel C) and reducing (panel D) conditions, and transferred 
to nitrocellulose membranes. The filters were analyzed by immunoblot- 
ting using MAb 1224 followed by 125I-labeled sheep anti-mouse IgG, 
and subjected toautoradiography. The migration of M, standards for 
panels A and B are indicated to thc left. Arrowheads denote the inter- 
face between stacking- and resolving el. 
separating gel. It should be noted that under educing condi- 
tions, native Vn partially aggregated tolower Mr multimers that 
are not present in the non-reducing ative PAGE gel (compare 
Fig. 1, panel C lane 1, and panel D lane 1). This observation 
may be related to a partial reversibility of the reduction during 
electrophoresis, resulting in free reactive cysteine residues that 
together with the expected high protein concentration at the 
interface between stacking and separating el may facilitate 
intermolecular disulfide xchange. This conclusion is supported 
by the finding that Vn multimers are formed in a concentration- 
dependent manner [6]. Taken together, these results support 
previous observation that Vn multimers are stabilized by cova- 
lent- and non-covalent interactions [7] and indicate that the Vn 
molecule was successfully denatured by the mild heat-treat- 
ment. 
In order to characterize conformational changes in the Vn 
molecule associated with the transition from the native to the 
modified form, relative reactivities of native and modified Vn 
with a panel of MAbs with known epitopes were determined 
using competitive immunoassays (Fig. 2). Increasing concen- 
trations of either native or modified Vn were co-incubated with 
a constant concentration f MAbs on Vn coated plates and 
assessed for ability to compete for binding of MAbs to immo- 
bilized, denatured Vn. The reactivities of the modified Vn with 
MAb 8E6 and with immobilized heparin were used as positive 
controls ince both binding sites are preferentially expressed in 
the denatured form [2]. Modified Vn reacted approximately 
10-fold better than native Vn with MAb 8E6 (Fig. 2, panel C) 
and interacted with immobilized heparin in a dose-dependent 
manner, whereas only weak binding of native Vn to heparin- 
coated microtiter wells was detected (Fig. 2, panel D). In con- 
trol experiments, modified Vn failed to bind to casein-blocked 
microtiter wells, indicating that the binding was specific (Fig. 
2, panel D). The reactivity of modified Vn with MAbs directed 
to the N-terminal somatomedin B domain (Fig. 2, panel A) or 
the immediately C-terminal connecting region/first hemopexin- 
like repeat (i.e, amino acid 52 239) was compared to native Vn. 
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Fig. 2. Exposure of conformationallyv sensitive pitopes in modified Vn. The indicated concentrations of native Vn (closed circles) or modified Vn 
(open circles) were co-incubated with a constant concentration of anti-Vn MAbs on microtiter wells coated with denatured Vn. The binding of the 
MAbs to immobilized Vn was detected with biotin-labeled goat anti-mouse IgG, followed by streptavidin alkaline phosphatase complex and substrate 
(see section 2). (A) MAb 153 (directed against amino acids 1~,0). (B) MAb 1244 (directed against amino acids 52-239). (C) MAb 8E6 (directed against 
amino acids 52-239; compare Fig. 4). In panel (D), the binding of native (closed circle) or modified Vn (open circle) to immobilized heparin was 
determined (see section 2). The binding of modified Vn to immobilized casein is indicated by the closed squares. 
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Fig. 3. lmmunoblotting analysis of the binding of MAbs to Vn and Vn 
fragments. Vn was cleaved with cyanogen bromide or acid hydrolyzed 
and fractionated by SDS-PAGE (14% acrylamide in the separating gel) 
and transferred to nitrocellulose membranes. The filters were incubated 
with MAb 8E6 (panel A) or MAb 1244 (panel B), followed by 125I- 
labeled sheep anti-mouse IgG. The membranes then were exposed to 
X-ray film for 16 h. (A and B) lanes 1 = uncleaved Vn; lanes 2 = cyan- 
ogen bromide cleaved Vn; lanes 3 = acid-hydrolyzed Vn. In panel (C), 
the Vn fragments (lane l = cyanogen bromide cleavage; lane 2 = acid- 
hydrolysis) were stained with Coomassie blue R250. The position of M, 
standards i indicated to the left. The arrowheads refer to the position 
of fragments of 40 and 35 kDa and the migration of the C-terminal 26 
kDa fragment is indicated by the arrow. 
The epitope mapping of these antibodies using defined Vn- 
fragments has been described previously [21]. Modified Vn 
reacted approximately 100-fold better than native Vn with both 
antibodies (Fig. 2, panels A and B). Similar results were ob- 
tained comparing the reactivity of native Vn with that of urea- 
treated native Vn (see section 2) or denatured Vn (not shown). 
Thus, conformational changes in the Vn molecule are not re- 
stricted to the heparin binding domain, but appear to occur also 
in the N-terminal somatomedin B domain and the connecting 
region/first hemopexin-like r peat. It should be noted that the 
regions in the Vn molecule recognized by the above antibodies 
have been recently reported to be destroyed upon denaturation 
and thus probably exposed in the native molecule [27]. At least 
two considerations may account for these differences. The Vn 
employed in this latter study was denatured by treatment with 
8M urea and in addition reduced, whereas the Vn employed in 
our study was only denatured by either heat- or urea-treatment 
in the absence of reducing agents. Thus, it remains unclear 
whether the loss of epitope expression in the Morris study is 
actually due to the conversion of the native to the conforma- 
tionally altered, denatured form, or general alterations in the 
protein structure due to reduction. Secondly, differences in 
epitope expression between ative and denatured Vn were not 
determined in solution, but upon immobilization of Vn to plas- 
tic wells. The latter treatment is reported to induce conforma- 
tional changes in the native Vn molecule [1]. 
The MAb 8E6 has been used as the standard to evaluate 
conformational changes in the Vn molecule upon ligand bind- 
ing [2,5,7]. The epitope for this antibody has been tentatively 
158 D. Seiffert/FEBS Letters 368 (1995) 155-159 
0 
z_ 
CJ 
Z 
m 
I.U 
0 
,¢ 
z 
LU 
0 
n- 
LU 
O. 
A 
100: 
80 
60 
40 
20 
0 
0 
biotinylated MAB 8E6 
1 5 lO 50 lOO 
IgG (ug/ml)  
o 
z 
z 
m 
LU 
O 
I-- 
Z 
uJ 
0 
n,. 
uJ 
a. 
B b io t iny la ted  MAB 1244 
1001 
80 
60 
40 
20 
0 
0 
i i = i 
1 5 10 50 100 
IgG (ug /ml )  
Fig. 4. Cross-competition f MAbs. Denatured Vn coated microtiter 
wells were incubated with a constant concentration of biotinylated 
MAb 8E6 (panel A) or biotinylated MAb 1244 (panel B) in the presence 
of increasing concentrations of unlabeled MAb 8E6 (closed circles), 
MAb 1244 (open circles), or MAb 153 (closed squares). Bound labeled 
antibody was detected with streptavidin alkaline phosphatase complex, 
followed by substrate. Results are expressed as percentage binding in 
the absence of unlabeled competitor. 
mapped based on functional studies (i.e. interference with li- 
gand binding in the heparin binding domain) to the C-terminal 
portion of the Vn molecule [4]. To reevaluate this assessment, 
the binding of MAb 8E6 to Vn-fragments derived from incom- 
plete acid hydrolysis and incomplete CNBr-cleavage was ana- 
lyzed by immunoblotting and compared to MAb 1244, previ- 
ously mapped to amino acids 52-239 [21]. Surprisingly in view 
of the reported results, the migration of the fragments detected 
by MAb 8E6 were very similar if not identical to that stained 
by MAb 1244 (Fig. 3). Specifically, both antibodies detected the 
M r 40,000 N-terminal Vn fragrnent derived from acid hydroly- 
sis (compare Fig. 3, panels A and B, lanes 3, arrowheads) and 
the Mr 35,000 fragment (amino acid 52 239) derived from 
cleavage by CNBr (Fig. 3, panels A and B, lanes 2, arrow- 
heads). It should be noted that the localization of these frag- 
ments in the intact Vn molecule was determined by N-terminal 
sequence analysis [20]. However, the M r 26,000 C-terminal frag- 
ment (Fig. 3, panel C, lane 2, arrow) derived from acid hydrol- 
ysis was present in the digest as revealed by Coomassie blue 
staining, but failed to react with both antibodies. Moreover, 
none of these antibodies stained the 12 kDa fragment derived 
from CNBr cleavage ncompassing the heparin binding domain 
(Fig. 3, panel C, lane 1) and incubation of the membranes 
without primary antibody abolished the specific signal (not 
shown). 
The relationship between the 8E6 and 1244 epitopes was 
further evaluated in competitive binding assays (Fig. 4). Unla- 
beled MAb 8E6 competed with the binding of biotinylated 
MAb 8E6 to immobilized Vn in a dose-dependent manner, 
whereas MAb 1244 only weakly interfered with the binding at 
relatively high IgG concentrations (Fig. 4, panel A). Con- 
sistently, only weak competition of MAb 8E6 with the binding 
of labeled MAb 1244 to immobilized Vn was detectable (Fig. 
4, panel B). Thus, although both antibodies interact with the 
CNBr cleavage-derived 35 kDa fragment (i.e. amino acid 52 
239), this functional assay revealed that these two epitopes are 
clearly distinct. 
It should be noted that the MAb 8E6 was recently reported 
to cross-react with a sulfated 30 kDa protein, and inhibition of 
sulfatation decreased the reactivity of this antibody for Vn and 
the 30 kDa protein, suggesting that sulfate, at least in part, may 
be part of the epitope recognized by MAb 8E6 [28]. The sites 
of tyrosine sulfatation have been mapped to residues 56 and 59 
in Vn [29]. In agreement with these observation, MAb 8E6 
failed to detect Vn polypeptides containing amino acid 52 239 
expressed in E. coli using the pET 15b expression plasmid 
(Novagen), whereas MAb 1244 strongly bound to this molecule 
(not shown). Taken together, these experiments strongly sug- 
gest that the 8E6 epitope is localized immediately upstream of 
the somatomedin B domain of the Vn molecule. 
Similar differences in the epitope xpression between ative 
and modified Vn were not restricted to the antibodies charac- 
terized in this study. For example, polyclonal antibodies de- 
rived from immunization with native Vn reacted approximately 
100-fold more strongly with denatured Vn in comparison to 
native Vn, and we were unable to identify MAbs specific for 
native Vn using a panel of more than 250 different hybridoma 
clones. Taken together, these results suggest hat the native 
form of the molecule is poorly immunogenic, onsistent with 
the high extent of cross-species conservation of both functional 
domains and primary structure [30]. 
In summary, this study provides evidence that conforma- 
tional changes in the Vn molecule upon denaturation are not 
limited to the heparin binding domain, suggestive of major 
molecular earrangements upon the transition of native to 
modified Vn. 
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